CAR-T与检查点抑制剂:急诊科中的毒性与解毒剂
本综述讨论嵌合抗原受体T(CAR-T)细胞治疗与免疫检查点抑制剂(ICI)相关的免疫相关不良事件(irAEs)。irAEs表现可能酷似常见疾病但可危及生命,详细询问过去一年肿瘤治疗史至关重要。CAR-T后细胞因子释放综合征(CRS)与免疫效应细胞相关神经毒性综合征(ICANS)若不及时识别处理可迅速进展至致命结局。ICI可影响任何器官系统,irAEs可表现为受累器官的典型自身免疫病。多数irAEs可从糖皮质激素治疗中获益,但需明确分级以决定治疗剂量、途径及后续管理。
要点
- 急诊医师与医学毒理学家应熟悉CAR-T与ICI的irAEs,详细询问患者过去一年的肿瘤治疗史以识别。
- CAR-T后CRS与ICANS若不及时识别和处理可迅速进展至致命结局。
- ICI的irAEs可影响任何器官系统,表现可酷似受累器官的典型自身免疫病。
- 多数irAEs可从糖皮质激素治疗中获益,但治疗剂量、途径及后续管理取决于irAEs的分级。
适用人群与场景
- 接受CAR-T细胞治疗或免疫检查点抑制剂(ICI)治疗的癌症患者,因相关就诊于急诊科
- 急诊医师与医学毒理学家需关注这类患者的免疫治疗相关毒性
诊断标准与关键阈值
- 细胞因子释放综合征(CRS)与免疫效应细胞相关神经毒性综合征(ICANS)可发生于CAR-T治疗后
- 需明确irAEs的分级,分级决定糖皮质激素的治疗剂量、给药途径及后续管理
处置流程与药物剂量
- 详细询问病史与体格检查,包括过去一年的癌症治疗史,对识别irAEs至关重要
- 多数irAEs可从糖皮质激素治疗中获益,具体剂量、途径需根据irAEs分级决定
红旗征与不能漏的情况
- CAR-T后CRS与ICANS若不及时识别和处理可迅速进展至致命结局
- irAEs表现可能酷似常见疾病,但可危及生命,需警惕
研究设计与关键结果
- 综述讨论CAR-T与ICI的免疫相关不良事件(irAEs)在急诊科的识别与管理
证据类型、等级与局限
- 证据类型:综述
- 局限:原文未报告局限性
对床旁实践的改变
- 急诊医师与医学毒理学家应牢记这些毒性及患者的肿瘤治疗史,以充分识别和管理这些情况(作者认为)。
- 对接受CAR-T或ICI治疗的患者,急诊评估应包括过去一年的癌症治疗史,以识别可能酷似常见疾病的irAEs。
- 多数irAEs可从糖皮质激素治疗中获益,但需先明确分级以决定剂量、途径和后续管理。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: New cancer treatments with immunotherapy have led to unique toxicities affecting cancer patients. As cancer-related visits to the emergency department increase, the emergency physician and the medical toxicologist should be aware of immunotherapy-related toxicities. In this review we discuss immune related adverse events (irAEs) from chimeric antigen receptor T (CAR-T) cell therapy and immune checkpoint inhibitors (ICI).
DISCUSSION: While presentation of the irAEs may mimic common conditions, it is important to recognize them as they may be life-threatening. A thorough history and examination of the patient, including their cancer treatment history in the past year is crucial. Conditions such as cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS), which can occur after CAR-T treatment, can progress rapidly to a fatal outcome if not recognized and managed in a timely manner. ICI can affect any organ system and irAEs may present like a typical autoimmune disease of the affected organ. While most of the irAEs we discuss in this review will benefit from treatment with glucocorticoids, it is important to know the grade of the condition, as it will determine the treatment dose, route and further management considerations.
CONCLUSION: Patients experiencing irAEs from ICI and CAR-T can present with subtle symptoms that can rapidly progress if not recognized early. The emergency physician and the medical toxicologist should keep in mind these toxicities and the patient's oncologic history to adequately recognize and manage these conditions.
参考来源
- Lipe DN, Shafer S. CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department. Clin Toxicol (Phila). 2021. PMID: 33576256. doi:10.1080/15563650.2021.1880008
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。